Physician profile
Myrdalis Diaz Ramirez
NPI 1033215546
$7,126.80
in general payments reported to CMS, 2019-2025
35 companies · $535 in 2025
The $535 reported for 2025 was more than what 91% of Integrative Medicine providers received nationally (typical 2025 total: $57.65).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,691 · 2020: $179 · 2021: $895 · 2022: $773 · 2023: $578 · 2024: $475 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $2,272.64 | 2019-2023 | Senza |
| Vertiflex, INC. | $1,506.58 | 2019 | |
| Abbott Laboratories | $550.60 | 2021-2025 | Proclaim, Eterna |
| Spr Therapeutics, INC | $466.73 | 2022-2025 | Sprint Pns System |
| Medtronic, INC. | $454.88 | 2021-2023 | Intellis Adaptivestim |
| Boston Scientific Corporation | $372.27 | 2020-2023 | |
| Pajunk Medical Systems, Lp | $142.36 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $137.84 | 2025 | Acuvue |
| Mml US, INC. | $132.57 | 2024 | Reactiv8 |
| Amgen INC. | $104.85 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $99.06 | 2023 | Quviviq |
| Curonix LLC | $90.60 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Scilex Pharmaceuticals INC. | $89.92 | 2019-2021 | |
| Nalu Medical, INC. | $63.33 | 2021-2022 | |
| Vertos Medical, INC. | $61.17 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $51.75 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $51.18 | 2021 | |
| Abbvie INC. | $50.18 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $42.10 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $42.10 | 2022 | |
| Novartis Pharmaceuticals Corporation | $38.30 | 2019-2020 | |
| Stimwave Technologies Incorporated | $35.18 | 2019 | |
| Medtronic USA, INC. | $30.40 | 2019-2020 | |
| Electronic Waveform Lab, INC. | $28.09 | 2019 | |
| Biodelivery Sciences International, INC. | $25.44 | 2021 | |
| Medline Industries Lp | $24.22 | 2022 | |
| Collegium Pharmaceutical, INC. | $24.08 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.20 | 2019 | |
| Forte Bio-Pharma LLC | $20.00 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $17.36 | 2019 | |
| Grt US Holding, INC. | $16.95 | 2019 | |
| Ibsa Pharma INC. | $16.62 | 2021 | |
| Daiichi Sankyo INC. | $16.27 | 2019 | |
| Horizon Therapeutics Plc | $15.94 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myrdalis Diaz Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.